摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-6-tert-butylamino-3,5-diflouropyridine | 189281-24-1

中文名称
——
中文别名
——
英文名称
2-amino-6-tert-butylamino-3,5-diflouropyridine
英文别名
2-amino-6-tert-butylamino-3,5-difluoropyridine;2-amino-6-(t-butylamino)-3,5-difluoropyridine;2-amino-6-(tert-butylamino)-3,5-difluoropyridine;2-amino-6-t-butylamino-3,5-difluoropyridine;N2-(tert-butyl)-3,5-difluoropyridine-2,6-diamine;6-N-tert-butyl-3,5-difluoropyridine-2,6-diamine
2-amino-6-tert-butylamino-3,5-diflouropyridine化学式
CAS
189281-24-1
化学式
C9H13F2N3
mdl
——
分子量
201.219
InChiKey
ZSICFDWRHQPJJR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    50.9
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-amino-6-tert-butylamino-3,5-diflouropyridine盐酸 、 lithium hydroxide monohydrate 、 lithium chloride四甲基胍 作用下, 以 乙醇二甲基亚砜 为溶剂, 反应 41.16h, 生成 7-(3-aminoazetidin-1-yl)-1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
    参考文献:
    名称:
    Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents
    摘要:
    Novel 7-(3-allcylaminoazetidin-1-yl)fluoroquinolones were designed, synthesized, and evaluated for their antibacterial activities and oral absorption rates. Against Gram-negative bacteria, 10a-e, which have various alkyl groups containing different numbers of carbon atoms (C0-C3) at the C-7 alkylaminoazetidine position, showed potent and similar antibacterial activities, whereas the activity of 10f (C4, t-Bu) was significantly lower than those of 10a-e. Conversely, the oral absorption rates of 10a-e in rats increased depending on the number of carbon atoms in the alkyl groups; 10d (C3, n-Pr) and 10e (C3, i-Pr) had high oral absorption rates (>90% at 10 mg/kg). These results demonstrated that the introduction of alkyl groups onto C-7 aminoazetidine is useful for the improvement of the oral absorption rates of these drugs while maintaining their antibacterial activities. As a conclusion, from this series of fluoroquinolones, WQ-3810 (10e), having 3-isopropylaminoazetidine as the C-7 substituent, was identified as an orally active antibacterial agent with a potent in vitro activity. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.08.015
  • 作为产物:
    描述:
    2,3,5,6-四氟吡啶盐酸 、 palladium 10% on activated carbon 、 氢气 作用下, 以 N-甲基吡咯烷酮甲醇乙腈 为溶剂, 反应 120.0h, 生成 2-amino-6-tert-butylamino-3,5-diflouropyridine
    参考文献:
    名称:
    Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents
    摘要:
    Novel 7-(3-allcylaminoazetidin-1-yl)fluoroquinolones were designed, synthesized, and evaluated for their antibacterial activities and oral absorption rates. Against Gram-negative bacteria, 10a-e, which have various alkyl groups containing different numbers of carbon atoms (C0-C3) at the C-7 alkylaminoazetidine position, showed potent and similar antibacterial activities, whereas the activity of 10f (C4, t-Bu) was significantly lower than those of 10a-e. Conversely, the oral absorption rates of 10a-e in rats increased depending on the number of carbon atoms in the alkyl groups; 10d (C3, n-Pr) and 10e (C3, i-Pr) had high oral absorption rates (>90% at 10 mg/kg). These results demonstrated that the introduction of alkyl groups onto C-7 aminoazetidine is useful for the improvement of the oral absorption rates of these drugs while maintaining their antibacterial activities. As a conclusion, from this series of fluoroquinolones, WQ-3810 (10e), having 3-isopropylaminoazetidine as the C-7 substituent, was identified as an orally active antibacterial agent with a potent in vitro activity. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.08.015
点击查看最新优质反应信息

文献信息

  • Pyridonecarboxylic acid derivatives or their salts and antibacterial
    申请人:Wakunaga Pharmaceuticals Co., Ltd.
    公开号:US05998436A1
    公开(公告)日:1999-12-07
    A pyridonecarboxylic acid derivative represented by the following general formula (1): ##STR1## [wherein R.sup.1 represents hydrogen atom or a carboxyl protective group; R.sup.2 represents hydroxyl group, a lower alkoxy group, or a substituted or unsubstituted amino group; R.sup.3 represents hydrogen atom or a halogen atom; R.sup.4 represents hydrogen atom or a halogen atom; R.sup.5 represents a halogen atom or an optionally substituted saturated cyclic amino group; R.sup.6 represents hydrogen atom, a halogen atom, nitro group, or an optionally protected amino group; X, Y and Z may be the same or different and respectively represent nitrogen atom, --CH.dbd. or --CR.sup.7 .dbd. (wherein R.sup.7 represents a lower alkyl group, a halogen atom, or cyano group) (with the proviso that at least one of X, Y and Z represent the nitrogen atom), and W represents nitrogen atom or --CR.sup.8 .dbd. (wherein R.sup.8 represents hydrogen atom, a halogen atom, or a lower alkyl group)] or its salt, as well as an antibacterial agent containing such compound are provided.
    一种吡啶酮羧酸衍生物,由以下通式(1)表示: ##STR1## [其中R1表示氢原子或羧基保护基团;R2表示羟基、低级烷氧基或取代或未取代的氨基;R3表示氢原子或卤素原子;R4表示氢原子或卤素原子;R5表示卤素原子或可选择性取代的饱和环状氨基;R6表示氢原子、卤素原子、硝基或可选择性保护的氨基;X、Y和Z可以相同或不同,分别表示氮原子、--CH=或--CR7=(其中R7表示低级烷基、卤素原子或氰基)(条件是X、Y和Z中至少有一个表示氮原子),W表示氮原子或--CR8=(其中R8表示氢原子、卤素原子或低级烷基)]或其盐,以及含有此类化合物的抗菌剂。
  • Pyridonecarboxylic acid derivatives or salts thereof and drugs
    申请人:Wakunaga Pharmaceutical Co., Ltd.
    公开号:US06136823A1
    公开(公告)日:2000-10-24
    The invention relates to pyridonecarboxylic acid derivatives represented by the general formula (1): ##STR1## wherein R.sup.1 is --OH, a carboxy-protecting group or (alkyl)amino group, R.sup.2 is H, or --NO.sub.2, (protected) amino, (protected) hydroxyl, lower alkyl or lower alkoxyl group, R.sup.3 is a halogen atom, H, or --NO.sub.2, lower alkyl, lower alkoxyl or amino group, R.sup.4 is an azido, (substituted) hydrazino, (substituted) amino, lower alkoxyl or hydroxyl group, R.sup.5, R.sup.6 and R.sup.7 are independently H, --NO.sub.2, halogen atom or lower alkyl group, R.sup.8 is a --NO.sub.2, (substituted) amino, --OH or lower alkoxyl group, A is N or C--R.sup.12, in which R.sup.12 is H, halogen atom, or (substituted) lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, lower alkylthio or nitro group, and B is N or C--R.sup.13, in which R.sup.13 is H or halogen atom, or salts thereof, and medicine comprising such a compound as an active ingredient. The derivatives or the salts thereof exhibit excellent antibacterial action and peroral absorbability, scarcely cause side effects, and are easy of synthesis.
    该发明涉及由通式(1)表示的吡啶酮羧酸衍生物:##STR1##其中R.sup.1为--OH、羧保护基团或(烷基)氨基团,R.sup.2为H或--NO.sub.2、(保护)氨基、(保护)羟基、较低烷基或较低烷氧基团,R.sup.3为卤素原子、H或--NO.sub.2、较低烷基、较低烷氧基或氨基团,R.sup.4为偶氮基、(取代)叠氮基、(取代)氨基、较低烷氧基或羟基团,R.sup.5、R.sup.6和R.sup.7独立地为H、--NO.sub.2、卤素原子或较低烷基团,R.sup.8为--NO.sub.2、(取代)氨基、--OH或较低烷氧基团,A为N或C--R.sup.12,其中R.sup.12为H、卤素原子或(取代)较低烷基、较低烯基、较低炔基、较低烷氧基、较低硫代烷基或硝基团,B为N或C--R.sup.13,其中R.sup.13为H或卤素原子,或其盐,以及包括此类化合物作为活性成分的药物。这些衍生物或其盐表现出优异的抗菌作用和口服吸收性,几乎不会引起副作用,并且易于合成。
  • Quinolinecarboxylic acid derivative or its salt
    申请人:Wakunaga Pharmaceutical Co., Ltd.
    公开号:US06586420B1
    公开(公告)日:2003-07-01
    The present invention relates a 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-hydroxyazetidin-1-yl)-8-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid or salt thereof; and drugs containing the same as the active ingredient. Since this compound or salt thereof is highly stable to light while sustaining the excellent properties inherent to quinolone antibacterial agents, an antibacterial agent comprising, as an active ingredient, the invention compound or salt thereof can be stored over a long period of time without suffering from any decrease in the drug effect and can therefore be supplied as stable preparations such as injections, eye drops and surgical medicines.
    本发明涉及一种1-(6-氨基-3,5-二氟吡啶-2-基)-6-氟-7-(3-羟基氮杂环戊烷-1-基)-8-甲基-1,4-二氢-4-氧喹诺酮-3-羧酸或其盐;以及含有该化合物作为活性成分的药物。由于该化合物或其盐对光高度稳定,同时保持喹诺酮类抗菌剂固有的优良特性,因此,包含该发明化合物或其盐作为活性成分的抗菌剂可以长时间存储,而不会出现药效降低,因此可以作为稳定的制剂,如注射剂、眼药水和外科药品供应。
  • Quinolinecarboxylic acid derivative or salts thereof
    申请人:Yazaki Akira
    公开号:US06858625B1
    公开(公告)日:2005-02-22
    This invention relates to 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof, and also to a medicine containing the same. This compound has characteristic features that, when administered orally, it has extremely high blood half-life and bioavailability while retaining properties that it has extremely high antimicrobial effects and has low toxicity. It can be used widely as preventives, therapeutics and the like for various infectious diseases of human and animals.
    本发明涉及1-(6-氨基-3,5-二氟吡啶-2-基)-8-溴-7-(3-乙基氨基氮杂环戊烷-1-基)-6-氟-4-氧代-1,4-二氢喹啉-3-羧酸或其盐,并且涉及含有该化合物的药物。该化合物具有特征性特点,当口服时,具有极高的血液半衰期和生物利用度,同时保持极高的抗微生物效果和低毒性。它可以广泛用于人类和动物的各种传染病的预防、治疗等。
  • Pyridonecarboxylic acid derivatives or their salts, and antibacterial
    申请人:Wakunaga Pharmaceutical Co., Ltd.
    公开号:US06133284A1
    公开(公告)日:2000-10-17
    A pyridonecarboxylic acid derivative represented by the following general formula (1): ##STR1## [wherein R.sup.1 represents hydrogen atom or a carboxyl protective group; R.sup.2 represents hydroxyl group, a lower alkoxy group, or a substituted or unsubstituted amino group; R.sup.3 represents hydrogen atom or a halogen atom; R.sup.4 represents hydrogen atom or a halogen atom; R.sup.5 represents a halogen atom or an optionally substituted saturated cyclic amino group; R.sup.6 represents hydrogen atom, a halogen atom, nitro group, or an optionally protected amino group; X, Y and Z may be the same or different and respectively represent nitrogen atom, --CH.dbd. or --CR.sup.7 .dbd. (wherein R.sup.7 represents a lower alkyl group, a halogen atom, or cyano group) (with the proviso that at least one of X, Y and Z represent the nitrogen atom), and W represents nitrogen atom or --CR.sup.8 .dbd. (wherein R.sup.8 represents hydrogen atom, a halogen atom, or a lower alkyl group)] or its salt, as well as an antibacterial agent containing such compound are provided.
    提供一种由以下通式(1)表示的吡啶酮羧酸衍生物:##STR1## [其中,R.sup.1表示氢原子或羧基保护基;R.sup.2表示羟基、低级烷氧基或取代或未取代的氨基;R.sup.3表示氢原子或卤素原子;R.sup.4表示氢原子或卤素原子;R.sup.5表示卤素原子或可选取代的饱和环氨基基团;R.sup.6表示氢原子、卤素原子、硝基基团或可选保护的氨基基团;X、Y和Z可以相同也可以不同,分别表示氮原子、--CH.dbd.或--CR.sup.7.dbd.(其中,R.sup.7表示低级烷基、卤素原子或氰基)(但至少其中一个为氮原子),W表示氮原子或--CR.sup.8.dbd.(其中,R.sup.8表示氢原子、卤素原子或低级烷基)]或其盐,以及含有此类化合物的抗菌剂。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-